Boc-L-丙氨醛 | 79069-50-4

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - BOC-氨基酸
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: Boc-L-丙氨醛
• 中文别名: 保护的丙氨酸醛；N-叔丁氧羰基-L-丙氨醛
• 英文名称: Boc-Ala-H
• 英文别名: tert-butyl (S)-(1-oxopropan-2-yl)carbamate；tert-butyl N-[(1S)-1-methyl-2-oxoethyl]carbamate；Boc-L-alaninal；tert-butyl N-[(2S)-1-oxopropan-2-yl]carbamate
• CAS: 79069-50-4
• 化学式: C₈H₁₅NO₃
• mdl: MFCD00143786
• 分子量: 173.212
• InChiKey: OEQRZPWMXXJEKU-LURJTMIESA-N

物化性质

• 熔点：
  76-77 °C
• 沸点：
  248.5±23.0 °C(Predicted)
• 密度：
  1.015±0.06 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• WGK Germany：
  3
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  -20°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-ala-aldehyde
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-ala-aldehyde
CAS number: 79069-50-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H15NO3
Molecular weight: 173.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Boc-L-丙氨醛 在 N-氯代丁二酰亚胺 、 盐酸羟胺 、 三乙胺 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 生成 tert-butyl N-[(2S)-1-chloro-1-hydroxyiminopropan-2-yl]carbamate
  参考文献：
  名称：

  Click化学中的铜（0）纳米颗粒：3,5-二取代的异恶唑的合成

  摘要：

  描述了一种通过易于制备的铜（0）纳米粒子通过原位生成的腈氧化物与乙炔的[3 + 2]环加成反应合成3,5-二取代的异恶唑的有效方法。各种原位生成的一氧化氮和炔属底物都参与了研究，并发现它们在短时间内发生环化反应，从而以优异的收率提供了各自的异恶唑。还以高收率制备了几种氨基酸衍生的异恶唑。发现回收的催化剂的一致活性直到三个循环几乎是相同的。

  DOI：

  10.1002/jhet.2065
• 作为产物：
  描述：

  N-tert-butoxycarbonyl-L-alanine ethyl ester 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 以74%的产率得到Boc-L-丙氨醛
  参考文献：
  名称：

  A SELECTIVE 1,2-REDUCTION OF γ-AMINO-α,β-UNSATURATED ESTERS BY MEANS OF BF₃·OEt₂-DIBAL-H SYSTEM. HIGHLY VERSATILE CHIRAL BUILDING BLOCKS FROM α-AMINO ACIDS

  摘要：

  DIBAL-H与BF3·OEt2的组合被证明是选择性1,2还原γ-氨基-α,β-不饱和酯的有前景的试剂，这一反应在其他情况下难以实现，并为从α-氨基酸获取有效的手性构建块提供了途径。

  DOI：

  10.1246/cl.1986.815

文献信息

• Synthesis and Characterization of Optically Pure Gamma‐ <scp>PNA</scp> Backbones by <scp>SIBX</scp> ‐Mediated Reductive Amination
  作者：Alagarsamy Periyalagan、Yong‐Tae Kim、In Seok Hong

  DOI：10.1002/bkcs.12365

  日期：2021.10

  Therefore, the synthesis of an optically pure γ-backbone is very important. Here, we report a novel synthetic strategy for the suppression of epimerization during the synthesis of the γ-PNA backbone. A stabilized form of 2-iodoxybenzoic acid (SIBX) was used as an oxidative reagent in the key intermediate of the N-Boc-amino acetaldehyde synthesis. This paper reports (1) the synthesis and comparison

  手性肽核酸 (PNA) 是常规 PNA 的衍生物，通过在其骨架上引入手性中心，并且已知比常规 PNA 与 DNA 或 RNA 的结合更强。特别是，在 γ-骨架的情况下，L异构体稳定 PNA/DNA 双链，而D-异构体具有相反的作用。因此，合成光学纯的γ-主链是非常重要的。在这里，我们报告了一种新的合成策略，用于在 γ-PNA 主链的合成过程中抑制差向异构化。稳定形式的 2-碘氧基苯甲酸 (SIBX) 在 N-Boc-氨基乙醛合成的关键中间体中用作氧化试剂。本文报道了 (1) 三种不同的 γ-PNA 骨架 (赖氨酸、丙氨酸和谷氨酸) 通过三种不同的合成路线 (SIBX、氢化铝锂和 Red-Al) 的合成和比较和 (2) 手性的测定其衍生化合物的纯度。SIBX 介导的 γ-PNA 骨架的对映体过量纯度被确定为超过 99.4%，由标准 RP-C18 柱上的高效液相色谱 (HPLC) 色谱图确定。它相对高于本工作中检查的其他方法。
• [EN] QUINOLONE DERIVATIVES AS ANTIBACTERIALS<br/>[FR] DÉRIVÉS DE QUINOLONE COMME ANTIBACTÉRIENS
  申请人：NOVARTIS AG

  公开号：WO2016020836A1

  公开（公告）日：2016-02-11

  This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I) as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.

  这项发明属于药物化学领域，涉及抑制细菌旋转酶的化合物及其制药组合物，这些化合物可用作抑制细菌旋转酶活性和细菌感染的药物，并具有如下所述的Formula (I)的结构。该发明还提供了包含Formula (I)化合物的药物组合物，以及使用这些化合物和组合物治疗细菌感染的方法。
• Inhibitors of P2X3
  申请人：Brotherton-Pleiss E. Christine

  公开号：US20070037974A1

  公开（公告）日：2007-02-15

  Compounds of formula 1 are modulators of P2X3 useful for the treatment of pain and genito-urinary, gastrointestinal, and respiratory disorders: wherein R 1 is —C(═S)CH 3 , pyridyl, pyrimidinyl, pyrazinyl, thiazolyl, furyl, furylcarbonyl, acetyl, or carbamoyl; R 2a and R 2b are independently H, methyl, or ethyl; R 3 is H or methyl; Y is a bond, —(CR 4 R 5 ) n — or —CR 4 ═CR 5 —; wherein R 4 and R 5 are each independently H or methyl and n is 1 or 2; X is N or CH; A is phenyl, 5-membered heterocyclyl, or 6-membered heterocyclyl; R 6 , R 7 and R 8 are each independently H, halo, lower alkyl, cycloalkyl, alkylthio, alkylthio-lower alkyl, alkylsulfonyl-lower alkyl, di(lower alkyl)amino-lower alkyl, morpholinyl-lower alkyl, 4-methyl-piperazinyl-methyl, trifluoromethyl, pyridyl, tetrazolyl, thiophenyl, phenyl, biphenyl, or benzyl (where thiophenyl, phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoromethyl, lower alkoxy or lower alkylthio) or R 6 and R 7 together form a 5-membered or 6-membered carbocyclic or heterocyclic ring substituted with 0-3 substituents selected from the group consisting of lower alkyl, lower alkoxy, oxo, halo, thiophenyl-lower alkyl, phenyl, benzyl (where phenyl and benzyl are substituted with 0-3 lower alkyl, halo, sulfonamido, trifluoro-methyl, lower alkoxy, lower alkylthio, amino-lower alkyl, lower alkylamino-lower alkyl, or di(lower alkyl)amino-lower alkyl); and pharmaceutically acceptable salts thereof; wherein when R 1 is pyrimidin-2-yl, X is N, Y is a bond and A is oxazol-5-yl the carbon atom at position 4 in said oxazol-5-yl is not substituted by propyl when the carbon atom at position 2 in said oxazol-5-yl is substituted by substituted phenyl and the carbon atom at position 4 in said oxazol-5-yl is not substituted by phenyl when the carbon atom at position 2 is substituted by unsubstituted or substituted phenyl.

  式1的化合物是P2X3的调节剂，用于治疗疼痛和泌尿生殖、胃肠和呼吸系统疾病： 其中 R 1 为—C(═S)CH 3 ，吡啶基，嘧啶基，吡嗪基，噻唑基，呋喃基，呋喃甲酰基，乙酰基或氨基甲酰基；R 2a 和R 2b 独立地为H，甲基或乙基；R 3 为H或甲基；Y为键，—(CR 4 R 5 ) n —或—CR 4 ═CR 5 —；其中R 4 和R 5 各自独立地为H或甲基，n为1或2；X为N或CH；A为苯基，5-成员杂环基或6-成员杂环基；R 6 ，R 7 和R 8 各自独立地为H，卤素，低碳基，环烷基，烷基硫醚，烷基硫醚-低碳基，烷基磺酰基-低碳基，二(低碳基)氨基-低碳基，吗啉基-低碳基，4-甲基哌嗪基-甲基，三氟甲基，吡啶基，四唑基，噻吩基，苯基，联苯基或苄基（其中噻吩基，苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基或低烷硫基取代）或R 6 和R 7 一起形成一个被0-3个取自由低碳基，低烷氧基，氧代基，卤素，噻吩基-低碳基，苯基，苄基（其中苯基和苄基被0-3个低碳基，卤素，磺酰胺基，三氟甲基，低烷氧基，低烷硫基，氨基-低碳基，烷基氨基-低碳基或二(低碳基)氨基-低碳基取代）的5-成员或6-成员碳环或杂环取代环；及其药学上可接受的盐；其中当R 1 为嘧啶-2-基时，X为N，Y为键，A为噁唑-5-基时，所述噁唑-5-基中位置4的碳原子在所述噁唑-5-基中位置2的碳原子被取代的苯基取代时不被丙基取代，且所述噁唑-5-基中位置4的碳原子在位置2被取代的苯基取代时不被苯基取代。
• Beta-carbolines useful for treating inflammatory disease
  申请人：Hepperle E. Michael

  公开号：US20050239781A1

  公开（公告）日：2005-10-27

  This invention provides beta-carboline compounds of formula III-A-aa: wherein Q, G, R 1 , R 2 , R 3 , and R 6b are as described in the specification. The compounds are useful for treating diseases such as inflammatory diseases and cancer.

  这项发明提供了III-A-aa式的β-咔啉化合物： 其中Q、G、R1、R2、R3和R6b如规范中所述。这些化合物可用于治疗炎症性疾病和癌症等疾病。
• [EN] NOVEL IMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'IMIDAZOLE
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2018216822A1

  公开（公告）日：2018-11-29

  Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salts thereof, that exhibit antimicrobial activity against gram-negative bacteria including multi-drug resistant strains and that are useful in the treatment of bacterial infections.

  提供了由以下一般式[1]表示的新化合物或其药用盐，其抑制LpxC，以及包含这些化合物或其药用盐的药物，对革兰氏阴性细菌包括多药耐药菌株表现出抗微生物活性，并且在治疗细菌感染中有用。